


Please cite the Published Version

Martí-Fàbregas, J, Guisado-Alonso, D, Delgado-Mederos, R, Martínez-Domeño, A, Prats-Sánchez, L, Guasch-Jiménez, M, Cardona, P, Núñez-Guillén, A, Requena, M, Rubiera, M, Olivé, M, Bustamante, A, Gomis, M, Amaro, S, Llull, L, Ustrell, X, de Oliveira, GC, Seró, L, Gomez-Choco, M, Mena, L, Serena, J, Viturro, SB, Purroy, F, Vicente, M, Rodríguez-Campello, A, Ois, A, Catena, E, Garcia-Carreira, MC, Barrachina, O, Palomeras, E, Krupinski, J , Almeria, M, Zaragoza, J, Esteve, P, Cocho, D, Moreira, A, van Eendenburg, C, Codas, JE, de la Ossa, NP, Salvat, M and Camps-Renom, P (2021) Impact of COVID-19 infection on the outcome of patients with ischemic stroke. *Stroke*, 52 (12). pp. 3908-3917. ISSN 0039-2499

DOI: <https://doi.org/10.1161/STROKEAHA.121.034883>

Publisher: Lippincott Williams & Wilkins/American Heart Association

Version: Supplemental Material

Downloaded from: <https://e-space.mmu.ac.uk/634369/>

Usage rights:  In Copyright

Additional Information: This is an accepted manuscript of an article which appeared in final form in *Stroke*, published by Lippincott Williams & Wilkins/American Heart Association

Enquiries:

If you have questions about this document, contact openresearch@mmu.ac.uk. Please include the URL of the record in e-space. If you believe that your, or a third party's rights have been compromised through this document please see our Take Down policy (available from <https://www.mmu.ac.uk/library/using-the-library/policies-and-guidelines>)

Table Supplemental I. Clinical characteristics of the patients with large-vessel occlusion (n=239)

	COVID-19 (n=39)	Non-COVID-19 (n=200)	p
NIHSS score, median (IQR)	16 (8-20)	16 (7-20)	0.374
Fibrinolysis, n (%)	12 (30.8)	66 (33.0)	0.786
Mechanical Thrombectomy, n (%)	18 (46.1)	118 (59.0)	0.234
Occluded artery, n (%)			
Extracranial ICA	6 (15.4)	14 (7.0)	0.606
Terminal ICA	5 (12.8)	22 (11.1)	
M1	11 (28.2)	91 (46.0)	
M2	13 (33.3)	52 (26.1)	
A1	0 (0.0)	2 (1.0)	
P1	0 (0.0)	3 (1.5)	
Basilar	1 (2.6)	5 (2.5)	
Vertebral	1 (2.6)	2 (1.0)	
Tandem ICA+M1	1 (2.6)	5 (2.5)	
Tandem ICA+M2	1 (2.6)	4 (2.0)	
TICI \geq 2b, n (%)	12 (30.7)	95 (48.0)	0.146

IQR=Interquartile range; NIHSS=National Institute of Health Stroke Scale;
TICI=Thrombolysis In Cerebral Ischemia

Table II Supplemental. Bivariate analyses of predictors of mortality at 90 days of follow-up

	HR	95% CI	p
Age, (y)	1.05	1.03-1.07	<0.001
Sex (men)	1.10	0.78-1.56	0.588
Obesity	0.65	0.36-1.15	0.135
High blood pressure	1.32	0.87-2.00	0.189
Diabetes	1.07	0.75-1.54	0.710
Hypercholesterolemia	1.19	0.84-1.68	0.337
Prior Stroke	1.33	0.89-1.97	0.159
Coronary artery disease	0.96	0.59-1.56	0.867
Atrial fibrillation	2.63	1.84-3.75	<0.001
Prior statins	1.09	0.77-1.54	0.628
Prior antiplatelet therapy	1.01	0.70-1.46	0.952
Prior anticoagulation	1.94	1.32-2.84	0.001
Prior ACE inhibitor	1.25	0.88-1.77	0.206
Baseline NIHSS score	1.11	1.09-1.14	<0.001
Admission to Stroke Unit	0.64	0.45-0.92	0.016
Admission to ICU	2.41	1.43-4.09	0.001
Confirmed COVID-19 infection	3.22	2.18-4.78	<0.001

ACE = Angiotensin Convertor Enzyme; CI = Confident Interval; HR = Hazard Ratio; ICU = Intensive Care Unit; IQR = Interquartile Range; NIHSS = National Institute of Health Stroke Scale; SD = Standard Deviation

Table Supplemental III. Bivariate and multivariable survival analyses of mortality at 90 days in patients with a SARS-CoV-2 PCR test available (n=495)

	HR	95% CI	p
Age, mean (SD)	1.05	1.03-1.07	<0.001
Sex (men), n (%)	1.08	0.73-1.60	0.686
High blood pressure, n (%)	1.18	0.76-1.85	0.460
Diabetes, n (%)	1.11	0.74-1.64	0.612
Hypercholesterolemia, n (%)	1.07	0.73-1.56	0.736
Prior Stroke, n (%)	1.08	0.69-1.70	0.716
Coronary artery disease, n (%)	0.92	0.55-1.55	0.766
Atrial fibrillation, n (%)	2.78	1.89-4.13	<0.001
Prior statins, n (%)	1.02	0.70-1.50	0.912
Prior antiplatelet therapy, n (%)	0.85	0.57-1.29	0.447
Prior anticoagulation, n (%)	2.06	1.35-3.13	0.001
Prior ACE inhibitor, n (%)	1.36	0.93-2.00	0.113
Baseline NIHSS score, median (IQR)	1.11	1.08-1.13	<0.001
Admission to Stroke Unit, n (%)	0.51	0.34-0.77	0.001
Admission to ICU, n (%)	1.86	1.04-3.33	0.037
Confirmed COVID-19 infection	2.88	1.91-4.35	<0.001
<i>Multivariable analysis</i>			
	HR	95% CI	p
Confirmed COVID-19 infection	2.77	1.80-4.25	<0.001
Age	1.06	1.04-1.08	<0.001
Atria fibrillation	1.67	1.09-2.56	0.018
Baseline NIHSS score	1.12	1.10-1.54	<0.001
Admission to the Stroke Unit	0.45	0.30-0.67	<0.001

ACE=Angiotensin Convertor Enzyme; ICU=Intensive Care Unit; HR=Hazard Ratio; IQR=Interquartile range; NIHSS=National Institute of Health Stroke Scale; SD=Standard Deviation

Table IV Supplemental. Cause of death

	All (n=131)	COVID-19 (n=36)	Non- COVID- 19 (n=95)
Unknown, n (%)	38 (29.0)	5 (13.9)	33 (34.7)
Malignant Stroke, n (%)	12 (9.2)	0 (0.0)	12 (12.6)
Stroke Complications (including recurrence and haemorrhagic complications), n (%)	17 (13.0)	2 (5.6)	15 (15.8)
Respiratory infection (including bronchoaspiration and other infections not related to COVID-19), n (%)	25 (19.1)	7 (19.4)	19 (20.0)
COVID-19 complications, n (%)	20 (15.3)	19 (52.8)	0 (0.0)
Cardiac complications (including cardiac arrest, cardiac failure and/or myocardial infarction), n (%)	7 (5.3)	1 (2.8)	6 (6.3)
Miscellanea (sepsis, cancer, hemostatic disorders, etc.), n (%)	12 (9.2)	2 (5.6)	10 (10.5)

Table Supplemental V. Markers of infection severity associated with mortality at 30 days in patients with ischemic stroke and COVID-19 infection

<i>Bivariate analysis</i>			
	Death (n=28)	Alive (n=63)	p
Baseline D-Dimer (ng/mL), median (IQR)	3029 (1070-5820)	1063 (535-2139)	0.007
Peak D-Dimer (ng/mL), median (IQR)	3029 (876-7333)	2481 (824-6000)	0.562
Obesity, n(%)	4 (14.3)	7 (11.1)	0.668
Baseline creatinin (mg/dL), median (IQR)	1.0 (0.74-1.37)	0.87 (0.64-0.99)	0.044
Peak creatinin (mg/dL), median (IQR)	1.01 (0.79-1.35)	0.86 (0.68-0.99)	0.012
Hypoxemia at any time (pO ₂ <60 mmHg), n(%)	18 (66.7)	24 (38.7)	0.015
Admission to the ICU, n (%)	7 (25.0)	19 (30.2)	0.615
Length of stay in ICU (days), mean (SD)	1.64 (6.0)	8.8 (18.1)	0.209
Mechanical ventilation, n (%)	4 (15.8)	16 (25.8)	0.287
Length of mechanical ventilation (days), mean (SD)	1.6 (6.5)	6.2 (15.2)	0.199
Diagnosis of acute respiratory distress syndrome, n (%)	15 (55.6)	20 (32.3)	0.039
Treatment with corticosteroids, n (%)	12 (42.9)	15 (23.8)	0.066
Treatment with azithromycin, n (%)	14 (50.0)	34 (54.0)	0.736
Treatment with remdesivir, n (%)	1 (3.6)	3 (4.8)	0.798
Treatment with anticoagulants, n (%)	5 (17.9)	31 (49.2)	0.005
Treatment with tocilizumab, n (%)	5 (17.9)	11 (17.5)	0.963
<i>Multivariate analysis</i>			
	HR	95% CI	p
Treatment with anticoagulants	0.24	0.07-0.81	0.022
Baseline D-Dimer levels (x1000ng/mL increase)	1.01	1.00-1.08	<0.001
Age	1.04	1.01-1.10	0.023
Baseline NIHSS	1.07	1.02-1.13	0.008
Admission to the Stroke Unit	0.19	0.05-0.70	0.013

HR=Hazard Ratio; IQR=Interquartile range; NIHSS=National Institute of Health Stroke Scale; SD=Standard Deviation




Figure I. Weekly proportion of patients with COVID-19 infection.